REFERENCE
Decision Resources.A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S. Media Release: 12 Jan 2009. Available from: URL: http://www.decisionresosurces.com
Rights and permissions
About this article
Cite this article
A biological drug that is superior to Boehringer Ingelheim/Pfizer's roflumilast [Spiriva] in reducing COPD exacerbations would earn a higher patient share in Europe. Pharmacoecon. Outcomes News 570, 10 (2009). https://doi.org/10.2165/00151234-200905700-00031
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905700-00031